BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34994963)

  • 1. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
    Grimaldi S; Harlay V; Appay R; Bequet C; Petrirena G; Campello C; BarriƩ M; Autran D; Boissonneau S; Graillon T; Figarella-Branger D; Nanni I; Chinot O; Tabouret E
    J Neurooncol; 2022 Feb; 156(3):615-623. PubMed ID: 34994963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases.
    Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W
    World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
    Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
    No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 7. H3K27M and
    Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
    Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
    World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
    Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
    CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
    Lu VM; Alvi MA; McDonald KL; Daniels DJ
    J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.
    Knight A; Horsley P; Yuile A; Yim J; Suh M; Venketesha V; Kastelan M; Wheeler H; Back M
    J Neurooncol; 2023 May; 163(1):281-288. PubMed ID: 37184742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
    Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
    World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
    Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
    CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review.
    Mohiuddin S; Maraka S; Usman Baig M; Gupta S; Muzzafar T; Valyi-Nagy T; Lindsay H; Moody K; Razvi S; Paulino A; Slavin K; Gondi V; McCutcheon I; Zaky W; Khatua S
    J Clin Neurosci; 2021 Jul; 89():405-411. PubMed ID: 34053821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
    Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
    Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral Thalamic Gliomas Harboring Alterations of EGFR and H3K27M: An Integrated Clinicopathological Characteristics Case Series.
    Xu K; Sun Z; Wang L; Guan W
    World Neurosurg; 2022 Dec; 168():e442-e450. PubMed ID: 36195182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.